Edward Feener Net Worth

The estimated Net Worth of Edward P. Feener is at least $6.65 Миллион dollars as of 17 May 2024. Mr. Feener owns over 18,789 units of KalVista Pharmaceuticals Inc stock worth over $867,741 and over the last 8 years he sold KALV stock worth over $4,187,064. In addition, he makes $1,590,710 as Chief Scientific Officer at KalVista Pharmaceuticals Inc.

Wallmine is a radically better financial terminal.
Sign up in seconds, it's free!

Sign up

Already have an account? Sign in

Mr. Feener KALV stock SEC Form 4 insiders trading

Edward has made over 24 trades of the KalVista Pharmaceuticals Inc stock since 2019, according to the Form 4 filled with the SEC. Most recently he exercised 18,789 units of KALV stock worth $201,418 on 17 May 2024.

The largest trade he's ever made was exercising 57,657 units of KalVista Pharmaceuticals Inc stock on 7 January 2022 worth over $434,734. On average, Edward trades about 9,593 units every 57 days since 2016. As of 17 May 2024 he still owns at least 80,946 units of KalVista Pharmaceuticals Inc stock.

You can see the complete history of Mr. Feener stock trades at the bottom of the page.

Edward Feener biography

Edward P. Feener Ph.D. serves as Chief Scientific Officer of the Company. Dr. Feener is a scientific co-founder of KalVista and joined as our Chief Scientific Officer in November 2016. Previously, Dr. Feener was an Associate Professor of Medicine at Harvard Medical School and Senior Investigator in the Section on Vascular Cell Biology at Joslin Diabetes Center from July 1989 to October 2016. He has more than 27 years of research experience in vascular biology and diabetic complications. His laboratory identified novel mechanisms of action for the plasma kallikrein system, which are implicated in diabetic macular edema, vascular injury, and angioedema. Dr. Feener received his Ph.D. in Biochemistry from Boston University and completed postdoctoral training at the Joslin Diabetes Center and Harvard Medical School.

What is the salary of Edward Feener?

As the Chief Scientific Officer of KalVista Pharmaceuticals Inc, the total compensation of Edward Feener at KalVista Pharmaceuticals Inc is $1,590,710. There are 1 executives at KalVista Pharmaceuticals Inc getting paid more, with Thomas Crockett having the highest compensation of $1,731,160.

How old is Edward Feener?

Edward Feener is 59, he's been the Chief Scientific Officer of KalVista Pharmaceuticals Inc since 2016. There are 6 older and 11 younger executives at KalVista Pharmaceuticals Inc. The oldest executive at KalVista Pharmaceuticals Inc is Arnold Oronsky, 80, who is the Independent Director.

What's Edward Feener's mailing address?

Edward's mailing address filed with the SEC is C/O KALVISTA PHARMACEUTICALS, INC., 55 CAMBRIDGE PARKWAY, SUITE 901E, CAMBRIDGE, MA, 02142.

Insiders trading at KalVista Pharmaceuticals Inc

Over the last 8 years, insiders at KalVista Pharmaceuticals Inc have traded over $74,823,944 worth of KalVista Pharmaceuticals Inc stock and bought 4,877,063 units worth $58,591,487 . The most active insiders traders include Holdings A/S Novo, Capital Management, L.P.Ra ... и Rajeev M. Shah. On average, KalVista Pharmaceuticals Inc executives and independent directors trade stock every 19 days with the average trade being worth of $835,088. The most recent stock trade was executed by Benjamin L Palleiko on 6 September 2024, trading 15,625 units of KALV stock currently worth $167,500.

What does KalVista Pharmaceuticals Inc do?

kalvista is a clinical stage pharmaceuticals company focused on the discovery, development, and commercialization of small molecule protease inhibitors.

Complete history of Mr. Feener stock trades at KalVista Pharmaceuticals Inc

KalVista Pharmaceuticals Inc executives and stock owners

KalVista Pharmaceuticals Inc executives and other stock owners filed with the SEC include:

• Thomas Crockett,
  Chief Executive Officer, Director
• Edward Feener,
  Chief Scientific Officer
• Benjamin Palleiko,
  Chief Financial Officer, Chief Business Officer
• Thomas Andrew Crockett M.B.A.,
  CEO & Director
• Christopher Yea,
  Chief Development Officer
• Benjamin L. Palleiko,
  Chief Bus. Officer & CFO
• Dr. Christopher M. Yea Ph.D.,
  Chief Devel. Officer
• Martin Edwards,
  Independent Chairman of the Board
• Edward Unkart,
  Independent Director
• Arnold Oronsky,
  Independent Director
• Albert Cha,
  Independent Director
• Brian Pereira,
  Independent Director
• Daniel Soland,
  Independent Director
• Michael Smith,
  Senior Vice President - Development
• Andreas Maetzel,
  Senior Vice President - Medical
• Jarrod Aldom,
  VP of Corp. Communications
• John B. McKune,
  VP of Fin.
• Stephen Donnelly,
  Director of Fin. and Company Sec.
• Dr. Paul K. Audhya M.B.A., M.D.,
  Chief Medical Officer
• Dr. Michael D. Smith Pharm.D.,
  Sr. VP of Devel.
• Rachel Morten,
  Head of Regulatory Affairs and QA
• Leah Monteiro,
  Sr. Director of Corp. Communications & Investor Relations
• Dr. Edward P. Feener Ph.D.,
  Chief Scientific Officer
• Joshua Resnick,
  Director
• Iv, Llcsv Life Sciences Fun...,
  
• Capital Management, Llc Kol...,
  
• Capital Management, L.P.Ra ...,
  
• Rajeev M. Shah,
  Director
• Healthcare Capital Partners...,
  
• Holdings A/S Novo,
  10% owner
• William Fairey,
  
• Paul K. Audhya,
  CHIEF MEDICAL OFFICER
• Healthcare Capital Partners...,
  
• Nancy Stuart,
  Director
• Patrick Treanor,
  Director
• Brian Piekos,
  Chief Financial Officer
• Healthcare Capital Partners...,